Elixir Company Update

Note 1: Undiluted capital structure (excluding options and performance rights). Note 2: Includes approx. 10.06 million shares to be issued to Elixir’s financial adviser for advisory services in relation to the Offer. Note 3: Cash is unaudited after FY25 R&D refund received on 3 November of $3.86 million Note 4: Estimated R&D refund up to 48% of eligible activities of Lorelle-3 subject to lodgement